BACKGROUND: Randomized studies have shown that bevacizumab combined with taxane-based regimens increases response rates and prolongs progression-free survival (PFS) of patients with metastatic breast cancer (MBC). However predictive or prognostic biological markers that identify the appropriate target population, thus improving the cost-effectiveness ratio of this treatment, are still needed. PATIENTS AND METHODS: Retrospectively, 124 patients with MBC treated either with paclitaxel 90 mg/m² weekly x12 plus bevacizumab 10 μg/kg every 2 weeks or 15 μg/kg every 3 weeks (85 patients) or paclitaxel 175 mg/m² plus bevacizumab 15 μg/kg every 3 weeks for 6 cycles (36 patients) were identified. Additionally, the prognostic significance of a panel of key biological markers was evaluated centrally by immunohistochemistry (IHC) in 88 evaluable patients. RESULTS: More than two thirds of the patients completed chemotherapy, as planned. The response rate was almost identical (55.3% vs. 55.6%) in the patients treated with weekly or 3-weekly paclitaxel, respectively. After a median follow-up time of 23 months, the median PFS of the study population was 13 months, while median survival had not yet been reached. Common severe adverse events were neutropenia (33%), neuropathy (18.6%) and metabolic disturbances (17.6%). The incidence of hypertension of all grades was 28.1%. High expression of vascular endothelial growth factor (VEGF) receptor 3 (VEGFR3) was associated with clinical response, while high expression of VEGFR1 was associated with poor survival. CONCLUSION: The safety and activity of the combination of bevacizumab with paclitaxel given either weekly or 3-weekly in patients with MBC is confirmed.
BACKGROUND: Randomized studies have shown that bevacizumab combined with taxane-based regimens increases response rates and prolongs progression-free survival (PFS) of patients with metastatic breast cancer (MBC). However predictive or prognostic biological markers that identify the appropriate target population, thus improving the cost-effectiveness ratio of this treatment, are still needed. PATIENTS AND METHODS: Retrospectively, 124 patients with MBC treated either with paclitaxel 90 mg/m² weekly x12 plus bevacizumab 10 μg/kg every 2 weeks or 15 μg/kg every 3 weeks (85 patients) or paclitaxel 175 mg/m² plus bevacizumab 15 μg/kg every 3 weeks for 6 cycles (36 patients) were identified. Additionally, the prognostic significance of a panel of key biological markers was evaluated centrally by immunohistochemistry (IHC) in 88 evaluable patients. RESULTS: More than two thirds of the patients completed chemotherapy, as planned. The response rate was almost identical (55.3% vs. 55.6%) in the patients treated with weekly or 3-weekly paclitaxel, respectively. After a median follow-up time of 23 months, the median PFS of the study population was 13 months, while median survival had not yet been reached. Common severe adverse events were neutropenia (33%), neuropathy (18.6%) and metabolic disturbances (17.6%). The incidence of hypertension of all grades was 28.1%. High expression of vascular endothelial growth factor (VEGF) receptor 3 (VEGFR3) was associated with clinical response, while high expression of VEGFR1 was associated with poor survival. CONCLUSION: The safety and activity of the combination of bevacizumab with paclitaxel given either weekly or 3-weekly in patients with MBC is confirmed.
Authors: A Stoyianni; G Pentheroudakis; H Benjamin; A Cervantes; K Ashkenazi; G Lazaridis; N Pavlidis; Y Spector Journal: Clin Transl Oncol Date: 2013-11-27 Impact factor: 3.405
Authors: George Fountzilas; Christos Christodoulou; Mattheos Bobos; Vassiliki Kotoula; Anastasia G Eleftheraki; Ioannis Xanthakis; Anna Batistatou; George Pentheroudakis; Nikolaos Xiros; Irene Papaspirou; Anna Koumarianou; Pavlos Papakostas; Dimitrios Bafaloukos; Dimosthenis V Skarlos; Konstantine T Kalogeras Journal: J Transl Med Date: 2012-10-23 Impact factor: 5.531
Authors: George Pentheroudakis; Vassiliki Kotoula; Anastasia G Eleftheraki; Eleftheria Tsolaki; Ralph M Wirtz; Konstantine T Kalogeras; Anna Batistatou; Mattheos Bobos; Meletios A Dimopoulos; Eleni Timotheadou; Helen Gogas; Christos Christodoulou; Kyriaki Papadopoulou; Ioannis Efstratiou; Chrisoula D Scopa; Irene Papaspyrou; Dimitrios Vlachodimitropoulos; Helena Linardou; Epaminontas Samantas; Dimitrios Pectasides; Nicholas Pavlidis; George Fountzilas Journal: PLoS One Date: 2013-07-29 Impact factor: 3.240
Authors: Flora Stavridi; Konstantine T Kalogeras; Kyriaki Pliarchopoulou; Ralph M Wirtz; Zoi Alexopoulou; Flora Zagouri; Elke Veltrup; Eleni Timotheadou; Helen Gogas; Angelos Koutras; Georgios Lazaridis; Christos Christodoulou; George Pentheroudakis; Apostolos Laskarakis; Petroula Arapantoni-Dadioti; Anna Batistatou; Maria Sotiropoulou; Gerasimos Aravantinos; Pavlos Papakostas; Paris Kosmidis; Dimitrios Pectasides; George Fountzilas Journal: PLoS One Date: 2016-10-03 Impact factor: 3.240